These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 28590364)

  • 1. Neurophysiological Effects of Bitopertin in Schizophrenia.
    Kantrowitz JT; Nolan KA; Epstein ML; Lehrfeld N; Shope C; Petkova E; Javitt DC
    J Clin Psychopharmacol; 2017 Aug; 37(4):447-451. PubMed ID: 28590364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms.
    Kantrowitz JT; Epstein ML; Lee M; Lehrfeld N; Nolan KA; Shope C; Petkova E; Silipo G; Javitt DC
    Schizophr Res; 2018 Jan; 191():70-79. PubMed ID: 28318835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.
    Umbricht D; Alberati D; Martin-Facklam M; Borroni E; Youssef EA; Ostland M; Wallace TL; Knoflach F; Dorflinger E; Wettstein JG; Bausch A; Garibaldi G; Santarelli L
    JAMA Psychiatry; 2014 Jun; 71(6):637-46. PubMed ID: 24696094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme.
    Bugarski-Kirola D; Iwata N; Sameljak S; Reid C; Blaettler T; Millar L; Marques TR; Garibaldi G; Kapur S
    Lancet Psychiatry; 2016 Dec; 3(12):1115-1128. PubMed ID: 27816567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pro-cognitive effects of the GlyT1 inhibitor Bitopertin in rodents.
    Deiana S; Hauber W; Munster A; Sommer S; Ferger B; Marti A; Schmid B; Dorner-Ciossek C; Rosenbrock H
    Eur J Pharmacol; 2022 Nov; 935():175306. PubMed ID: 36183855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind randomized study assessing safety and efficacy following one-year adjunctive treatment with bitopertin, a glycine reuptake inhibitor, in Japanese patients with schizophrenia.
    Hirayasu Y; Sato S; Takahashi H; Iida S; Shuto N; Yoshida S; Funatogawa T; Yamada T; Higuchi T
    BMC Psychiatry; 2016 Mar; 16():66. PubMed ID: 26980460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia - results from the CandleLyte study.
    Bugarski-Kirola D; Wang A; Abi-Saab D; Blättler T
    Eur Neuropsychopharmacol; 2014 Jul; 24(7):1024-36. PubMed ID: 24735806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurophysiological mechanisms of cortical plasticity impairments in schizophrenia and modulation by the NMDA receptor agonist D-serine.
    Kantrowitz JT; Epstein ML; Beggel O; Rohrig S; Lehrfeld JM; Revheim N; Lehrfeld NP; Reep J; Parker E; Silipo G; Ahissar M; Javitt DC
    Brain; 2016 Dec; 139(Pt 12):3281-3295. PubMed ID: 27913408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the glycine reuptake inhibitors bitopertin and RG7118 on glycine in cerebrospinal fluid: results of two proofs of mechanism studies in healthy volunteers.
    Hofmann C; Pizzagalli F; Boetsch C; Alberati D; Ereshefsky L; Jhee S; Patat A; Boutouyrie-Dumont B; Martin-Facklam M
    Psychopharmacology (Berl); 2016 Jul; 233(13):2429-39. PubMed ID: 27178435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bitopertin in Negative Symptoms of Schizophrenia-Results From the Phase III FlashLyte and DayLyte Studies.
    Bugarski-Kirola D; Blaettler T; Arango C; Fleischhacker WW; Garibaldi G; Wang A; Dixon M; Bressan RA; Nasrallah H; Lawrie S; Napieralski J; Ochi-Lohmann T; Reid C; Marder SR
    Biol Psychiatry; 2017 Jul; 82(1):8-16. PubMed ID: 28117049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.
    Hofmann C; Banken L; Hahn M; Swearingen D; Nagel S; Martin-Facklam M
    Clin Ther; 2012 Oct; 34(10):2061-71. PubMed ID: 22980315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bitopertin: the good news and bad news.
    Goff DC
    JAMA Psychiatry; 2014 Jun; 71(6):621-2. PubMed ID: 24696065
    [No Abstract]   [Full Text] [Related]  

  • 13. Glycine Transporter Type I (GlyT1) Inhibitor, Bitopertin: A Journey from Lab to Patient.
    Pinard E; Borroni E; Koerner A; Umbricht D; Alberati D
    Chimia (Aarau); 2018 Aug; 72(7):477-484. PubMed ID: 30158010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of glycine transporter 1: The yellow brick road to new schizophrenia therapy?
    Singer P; Dubroqua S; Yee BK
    Curr Pharm Des; 2015; 21(26):3771-87. PubMed ID: 26205290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycine transport inhibitors in the treatment of schizophrenia.
    Javitt DC
    Handb Exp Pharmacol; 2012; (213):367-99. PubMed ID: 23027421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia.
    Javitt DC; Zukin SR; Heresco-Levy U; Umbricht D
    Schizophr Bull; 2012 Sep; 38(5):958-66. PubMed ID: 22987851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rodent Mismatch Negativity/theta Neuro-Oscillatory Response as a Translational Neurophysiological Biomarker for N-Methyl-D-Aspartate Receptor-Based New Treatment Development in Schizophrenia.
    Lee M; Balla A; Sershen H; Sehatpour P; Lakatos P; Javitt DC
    Neuropsychopharmacology; 2018 Feb; 43(3):571-582. PubMed ID: 28816240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haematological effects of oral administration of bitopertin, a glycine transport inhibitor, in patients with non-transfusion-dependent β-thalassaemia.
    Taher AT; Viprakasit V; Cappellini MD; Kraus D; Cech P; Volz D; Winter E; Nave S; Dukart J; Khwaja O; Koerner A; Hermosilla R; Brugnara C
    Br J Haematol; 2021 Jul; 194(2):474-477. PubMed ID: 33931857
    [No Abstract]   [Full Text] [Related]  

  • 19. Dose-Dependent Augmentation of Neuroplasticity-Based Auditory Learning in Schizophrenia: A Double-Blind, Placebo-Controlled, Randomized, Target Engagement Clinical Trial of the NMDA Glutamate Receptor Agonist d-serine.
    Sehatpour P; Iosifescu DV; De Baun HM; Shope C; Mayer MR; Gangwisch J; Dias E; Sobeih T; Choo TH; Wall MM; Medalia A; Saperstein AM; Kegeles LS; Girgis RR; Carlson M; Kantrowitz JT
    Biol Psychiatry; 2023 Jul; 94(2):164-173. PubMed ID: 36958998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycine transporter type 1 occupancy by bitopertin: a positron emission tomography study in healthy volunteers.
    Martin-Facklam M; Pizzagalli F; Zhou Y; Ostrowitzki S; Raymont V; Brašić JR; Parkar N; Umbricht D; Dannals RF; Goldwater R; Wong DF
    Neuropsychopharmacology; 2013 Feb; 38(3):504-12. PubMed ID: 23132267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.